Haselmeier

What Haselmeier does

Haselmeier is the drug delivery device business of medmix Group AG (SIX: MEDX), a publicly traded Swiss parent. Founded in 1920 in Stuttgart, Germany, Haselmeier designs and manufactures subcutaneous self-injection devices for pharmaceutical and biotechnology customers, with a portfolio spanning autoinjectors and injection pens. The company operates four manufacturing sites in Germany (Stuttgart headquarters plus Buchen), the Czech Republic (Dnešice), India (Bangalore), and the United States (Atlanta), employing approximately 280 international staff. Haselmeier pioneered the first commercial autoinjector in 1963 (Diarapid) and has since developed a succession of injection platforms including DIAPEN, Pentek, Re-Vario, Axis-D, D-Flex, and most recently PiccoJect.

Haselmeier's product portfolio is organized around two main categories. The autoinjector line is led by PiccoJect, a compact two-step disposable platform built from only eight parts and available in 1 mL and 2.25 mL variants. The injection pen line includes D-Flex (disposable, fixed-dose, with a smart cap Bluetooth digital option), Re-Vario (reusable variable-dose), and in-pen reconstitution systems for lyophilized biologics. The company protects its innovations through more than 200 granted patents and a portfolio of registered trademarks, and it maintains ISO 13485, MDSAP, EU MDR, EcoVadis Gold, and CDP A-level certifications across its manufacturing footprint.

The business model is enterprise B2B, with quote-based pricing for device platforms, contract development services (combination product development, design verification, final assembly, secondary packaging, labeling, and serialization), and platform licensing. Customers include Sanofi-Aventis (TactiPen, JuniorSTAR), Berlin-Chemie (BerliPen areo), Biocon (INSUPen), and Roche (GLP-1 collaboration via Enable Injections). Go-to-market is executed through regional business development managers covering EMEA, Japan, the US, and India, supplemented by an exclusive distribution partnership with NIPRO Corporation for Japan (April 2024) and active presence at industry events such as PDA Universe, Pharmapack, and DCAT Week. The 2023 strategic 25% investment in AARDEX Group extends the offering into digital medication adherence solutions for clinical trials.

Name

Haselmeier

Legal name

Haselmeier GmbH

Website

https://haselmeier.com

Company type

Private

Founded year

1920

Operating status

Operating

Headcount range

101–250 employees

Short description

Haselmeier, the drug delivery business of medmix Group AG, designs and manufactures subcutaneous self-injection devices including the PiccoJect autoinjector and D-Flex, Re-Vario, and reconstitution pen platforms. The Germany-based company serves pharmaceutical and biotechnology customers globally from four manufacturing sites spanning Europe, the US, and India.

Ownership category

akta.pro rank

Product category

Drug Delivery Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Pen Injectors (Insulin/GLP-1/Other Pens) (HLAHAIAC)

akta.pro secondary industries

Auto-Injectors (Disposable & Reusable) (HLAHAIAB), Insulin Pen Needles, Syringes & Infusion Sets (Consumables) (HLAHAHAE)

Keywords

• Drug delivery devices
• Subcutaneous injection systems
• Autoinjector manufacturing
• Injection pen platforms
• Combination product development

Headquarters

HQ city

Stuttgart

HQ country

Germany

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Drug Delivery Device Manufacturing: Manufacturing and sale of autoinjectors and injection pens to pharmaceutical and biotech companies for combination product development.
2. Contract Development Services: Full-service platform including combination product development, design verification, final assembly, secondary packaging, labeling and serialization for pharma customers.
3. Platform Licensing: Licensing of proprietary device platforms (PiccoJect, D-Flex, Re-Vario) to pharmaceutical companies for drug-specific customization.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Haselmeier designs, develops, and manufactures injection pens and autoinjectors for subcutaneous self-administration of drugs. The company offers proprietary platforms including PiccoJect (autoinjector), D-Flex and Re-Vario (injection pens), and in-pen reconstitution systems, primarily serving pharmaceutical and biotechnology customers developing combination products for chronic and acute therapies.

Product overview

Haselmeier, the drug delivery business of medmix, is a global medical device manufacturer specializing in advanced injection pen systems and autoinjectors for subcutaneous self-administration. The portfolio includes two main product categories: autoinjectors (PiccoJect) and injection pens (D-Flex, Re-Vario, In-Pen Reconstitution). PiccoJect is a 2-step disposable autoinjector available in 1 mL and 2.25 mL versions. D-Flex is a disposable injection pen with unique fixed-dose technology. Re-Vario is a reusable variable-dose pen. In-Pen Reconstitution enables mixing and injecting drugs from dual-chamber cartridges. Additionally, Haselmeier offers digital solutions including D-Flex Connect (Bluetooth smart cap) and Smart MEMS Cap for clinical trial adherence monitoring. Full-service capabilities span consulting, project management, industrialization and manufacturing, and life cycle management.

Differentiator

Problem solved

Functional benefit

Brands

• PiccoJect: Highly compact, fully-featured 2-step autoinjector for subcutaneous drug delivery, available in 1 mL and 2.25 mL versions. Awarded Good Design Award 2022 and Red Dot Award 2023.
• D-Flex
• Re-Vario
• Reconstitution

Products and services

• PiccoJect Autoinjector
• D-Flex Injection Pen
• Re-Vario Injection Pen
• In-Pen Reconstitution Systems
• D-Flex Connect Smart Cap
• Smart MEMS Cap
• Combination Product Development Services

Quantifiable outcome

• 92% of study participants preferred PiccoJect over benchmark devices
• +4 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and supporting.

• NIPRO CorporationcoreChannel Partner/ Reseller/ Distributor · 16 April 2024Exclusive promotion and distribution partnership for PiccoJect autoinjector in Japanese market. Nipro leverages extensive reach and reputation in pharmaceutical packaging to expand Haselmeier's Asia-Pacific presence. PiccoJect available through Nipro from Q1/2025.
• AARDEX GroupcoreStrategic or Co-development Partner · 17 October 2023medmix acquired 25% strategic stake in AARDEX through Series B investment. Partnership combines Haselmeier drug delivery devices with AARDEX MEMS digital medication adherence monitoring solutions for clinical trials. Enables end-to-end service with digital adherence solutions alongside delivery devices.
• Nipro PharmaPackagingsupportingTechnology or Integration · 25 May 2023Successful compatibility testing confirmed between PiccoJect 100 autoinjector and Nipro D2F pre-fillable syringes. Enables customers to use Nipro syringes with Haselmeier autoinjectors.
• DCA Design InternationalsupportingStrategic or Co-development Partner · 6 April 2023Product design partnership for PiccoJect autoinjector development. Jointly received Red Dot Award 2023 and Good Design Award 2022 for PiccoJect design excellence.
• plus10 GmbHsupportingTechnology or Integration · 10 March 2022Joint project implementing plus10 Shannon AI-based software on Haselmeier's automated assembly lines for injection syringes. Won Microsoft Intelligent Manufacturing Award 2021 'Innovate' category for achieving 10%+ productivity improvement through real-time problem identification.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Ypsomed Holding AG: Swiss-headquartered manufacturer of injection pens and autoinjectors (YpsoMate, UnoPen, ServoPen); the closest direct peer to Haselmeier in disposable/reusable pens and 2-step autoinjectors serving the same pharma combination-product customers.
• SHL Medical AG: Global leader in autoinjector design and manufacturing (Molly, Molly 2.0); competes head-to-head with Haselmeier for pharma combination-product autoinjector programs, including high-volume biologics.
• West Pharmaceutical Services: US-listed drug delivery device and containment provider offering SmartDose, SelfDose and other wearable/autoinjector platforms; competes directly with Haselmeier for combination-product contracts.
• Owen Mumford: UK-headquartered specialist in auto-injectors (Autoject, Aidaptus) and pen injectors; directly comparable to Haselmeier as a family-owned drug delivery device specialist serving pharma combination products.
• Stevanato Group: Italian-listed provider of drug containment, delivery and diagnostic solutions including the Aidaptus autoinjector platform (with Owen Mumford); competes with Haselmeier in pre-filled syringe-based combination products.

Broad incumbents

• Becton, Dickinson and Company (BD): Global medical technology incumbent with a large Pharmaceutical Systems segment producing pre-filled syringes, autoinjectors and pen components; broad incumbent competing across multiple device modalities where Haselmeier is active.
• Gerresheimer AG: German-headquartered primary packaging and drug delivery group offering Gx InnoSafe, syringes and pen components; a broad European incumbent overlap with Haselmeier in glass-based combination-product components.

Emerging players

• Enable Injections: US-based developer of the enFuse large-volume wearable delivery platform; an emerging competitor addressing high-volume biologics and GLP-1 delivery that Haselmeier's PiccoJect 225 and wearable/in-pen offerings will increasingly face in pharma RFPs.

Others

• Nipro Corporation (NIPRO PharmaPackaging): Japanese medical device and pharma packaging company with pre-fillable syringe systems (D2F) and exclusive distribution partner for Haselmeier's PiccoJect in Japan; an adjacent player also supplying drug-delivery components to the same pharma clients.
• AARDEX Group: Digital medication adherence (MEMS) specialist in which medmix holds a 25% strategic stake; a partner/adjoining ecosystem participant whose adherence technology is bundled with Haselmeier devices for clinical trials.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCvizND8pTvohKP3OomOYczA
• LinkedInlinkedin.com/showcase/haselmeier
• Xx.com/haselmeiergroup

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Haselmeier